Peripheral Biomarkers of Major Depression and Antidepressant Treatment Response: Current Knowledge and Future Outlooks

Overview

Journal J Affect Disord

Date 2017 Jul 16

PMID 28709695

Citations 66

Authors

Bharathi S Gadad

Manish K Jha

Andrew Czysz

Jennifer L Furman

Taryn L Mayes

Michael P Emslie

Madhukar H Trivedi

Affiliations

Soon will be listed here.

Abstract

Background: In recent years, we have accomplished a deeper understanding about the pathophysiology of major depressive disorder (MDD). Nevertheless, this improved comprehension has not translated to improved treatment outcome, as identification of specific biologic markers of disease may still be crucial to facilitate a more rapid, successful treatment. Ongoing research explores the importance of screening biomarkers using neuroimaging, neurophysiology, genomics, proteomics, and metabolomics measures.

Results: In the present review, we highlight the biomarkers that are differentially expressed in MDD and treatment response and place a particular emphasis on the most recent progress in advancing technology which will continue the search for blood-based biomarkers.

Limitations: Due to space constraints, we are unable to detail all biomarker platforms, such as neurophysiological and neuroimaging markers, although their contributions are certainly applicable to a biomarker review and valuable to the field.

Conclusions: Although the search for reliable biomarkers of depression and/or treatment outcome is ongoing, the rapidly-expanding field of research along with promising new technologies may provide the foundation for identifying key factors which will ultimately help direct patients toward a quicker and more effective treatment for MDD.

Citing Articles

Unveiling the Mechanisms of a Remission in Major Depressive Disorder (MDD)-like Syndrome: The Role of Hippocampal Palmitoyltransferase Expression and Stress Susceptibility.

Schroeter C, Gorlova A, Sicker M, Umriukhin A, Burova A, Shulgin B Biomolecules. 2025; 15(1).

PMID: 39858460 PMC: 11764023. DOI: 10.3390/biom15010067.

Bipolar disorders: an update on critical aspects.

Oliva V, Fico G, De Prisco M, Gonda X, Rosa A, Vieta E Lancet Reg Health Eur. 2025; 48():101135.

PMID: 39811787 PMC: 11732062. DOI: 10.1016/j.lanepe.2024.101135.

Enhancing Transcriptomic Insights into Neurological Disorders Through the Comparative Analysis of Shapley Values.

Castro-Martinez J, Vargas E, Diaz-Beltran L, Esteban F Curr Issues Mol Biol. 2024; 46(12):13583-13606.

PMID: 39727940 PMC: 11726880. DOI: 10.3390/cimb46120812.

Identification of molecular targets of Hypericum perforatum in blood for major depressive disorder: a machine-learning pharmacological study.

Xu Z, Rasteh A, Dong A, Wang P, Liu H Chin Med. 2024; 19(1):141.

PMID: 39385284 PMC: 11465934. DOI: 10.1186/s13020-024-01018-5.

The Effects of Variation in the GABA Receptor Gene on Anxious Depression are Mediated by the Functional Connectivity Between the Amygdala and Middle Frontal Gyrus.

Qiao J, Tao S, Sun Y, Shi J, Chen Y, Tian S Neuropsychiatr Dis Treat. 2024; 20:1781-1796.

PMID: 39346029 PMC: 11438461. DOI: 10.2147/NDT.S468290.

References

Trivedi M, Rush A, Wisniewski S, Nierenberg A, Warden D, Ritz L . Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006; 163(1):28-40. DOI: 10.1176/appi.ajp.163.1.28. View

Abo R, Hebbring S, Ji Y, Zhu H, Zeng Z, Batzler A . Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet Genomics. 2012; 22(4):247-53. PMC: 3303952. DOI: 10.1097/FPC.0b013e32835001c9. View

Trivedi M, Morris D, Pan J, Grannemann B, Rush A . What moderator characteristics are associated with better prognosis for depression?. Neuropsychiatr Dis Treat. 2008; 1(1):51-7. PMC: 2426815. DOI: 10.2147/nedt.1.1.51.52298. View

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

Ji Y, Hebbring S, Zhu H, Jenkins G, Biernacka J, Snyder K . Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther. 2010; 89(1):97-104. PMC: 3034442. DOI: 10.1038/clpt.2010.250. View

Martins-de-Souza D . Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive disorder. Dialogues Clin Neurosci. 2014; 16(1):63-73. PMC: 3984892. View

Porcelli S, Fabbri C, Spina E, Serretti A, De Ronchi D . Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. Expert Opin Drug Metab Toxicol. 2011; 7(9):1101-15. DOI: 10.1517/17425255.2011.597740. View

Olfson M, Marcus S . National patterns in antidepressant medication treatment. Arch Gen Psychiatry. 2009; 66(8):848-56. DOI: 10.1001/archgenpsychiatry.2009.81. View

Demirkan A, Isaacs A, Ugocsai P, Liebisch G, Struchalin M, Rudan I . Plasma phosphatidylcholine and sphingomyelin concentrations are associated with depression and anxiety symptoms in a Dutch family-based lipidomics study. J Psychiatr Res. 2012; 47(3):357-62. DOI: 10.1016/j.jpsychires.2012.11.001. View

10.

Buttenschon H, Foldager L, Elfving B, Poulsen P, Uher R, Mors O . Neurotrophic factors in depression in response to treatment. J Affect Disord. 2015; 183:287-94. DOI: 10.1016/j.jad.2015.05.027. View

11.

Benedetti F, Colombo C, Pirovano A, Marino E, Smeraldi E . The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology (Berl). 2008; 203(1):155-60. DOI: 10.1007/s00213-008-1381-7. View

12.

Kessler R, Berglund P, Demler O, Jin R, Koretz D, Merikangas K . The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23):3095-105. DOI: 10.1001/jama.289.23.3095. View

13.

Lopez J, Mamdani F, Labonte B, Beaulieu M, Yang J, Berlim M . Epigenetic regulation of BDNF expression according to antidepressant response. Mol Psychiatry. 2012; 18(4):398-9. PMC: 5319860. DOI: 10.1038/mp.2012.38. View

14.

Ball S, Classi P, Dennehy E . What happens next?: a claims database study of second-line pharmacotherapy in patients with major depressive disorder (MDD) who initiate selective serotonin reuptake inhibitor (SSRI) treatment. Ann Gen Psychiatry. 2014; 13(1):8. PMC: 3994945. DOI: 10.1186/1744-859X-13-8. View

15.

Martins-de-Souza D, Harris L, Guest P, Turck C, Bahn S . The role of proteomics in depression research. Eur Arch Psychiatry Clin Neurosci. 2009; 260(6):499-506. PMC: 2940035. DOI: 10.1007/s00406-009-0093-2. View

16.

Rush A, Trivedi M, Wisniewski S, Stewart J, Nierenberg A, Thase M . Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006; 354(12):1231-42. DOI: 10.1056/NEJMoa052963. View

17.

Assies J, Pouwer F, Lok A, Mocking R, Bockting C, Visser I . Plasma and erythrocyte fatty acid patterns in patients with recurrent depression: a matched case-control study. PLoS One. 2010; 5(5):e10635. PMC: 2871041. DOI: 10.1371/journal.pone.0010635. View

18.

Oh G, Wang S, Pal M, Chen Z, Khare T, Tochigi M . DNA modification study of major depressive disorder: beyond locus-by-locus comparisons. Biol Psychiatry. 2014; 77(3):246-255. PMC: 4277915. DOI: 10.1016/j.biopsych.2014.06.016. View

19.

Uher R, Tansey K, Dew T, Maier W, Mors O, Hauser J . An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry. 2014; 171(12):1278-86. DOI: 10.1176/appi.ajp.2014.14010094. View

20.

Hogeweg P . The roots of bioinformatics in theoretical biology. PLoS Comput Biol. 2011; 7(3):e1002021. PMC: 3068925. DOI: 10.1371/journal.pcbi.1002021. View